The concept has been around for more than a century, but recent advances in the field are causing numerous experts to say it’s widely underused. The goal of allergen immunotherapy (AIT) is to induce a specific immune tolerance by confronting patients with increasing levels of allergens. AIT developers are now working on improving efficacy and safety, while at the same time trying to speed up the still lengthy process of desensitisation. Peanuts in particular are in the crosshairs, as they cause one of the most life-threatening common allergies in humans.
Sygnis AG: Science and business rolled into one
AppointmentsGerman-Spanish biotech Sygnis AG has made changes to its management team and supervisory board. Heikki Lanckriet, who was previously Co-CEO, will become sole CEO of Sygnis and will also retain his role as Chief Scientific Officer.
Noxxon/MSD start testing of immunoncologic combo
Latest NewsLast December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.
ReadyTector Immunodetection
ProductsReadyTector is an easy, quick and clear all-in-one detection solution for Western blotting.
Allergies: Public Enemy Number One
BackgroundThe concept has been around for more than a century, but recent advances in the field are causing numerous experts to say it’s widely underused. The goal of allergen immunotherapy (AIT) is to induce a specific immune tolerance by confronting patients with increasing levels of allergens. AIT developers are now working on improving efficacy and safety, while at the same time trying to speed up the still lengthy process of desensitisation. Peanuts in particular are in the crosshairs, as they cause one of the most life-threatening common allergies in humans.
Exscientia inks €37m contract with GSK
Latest NewsBritish pharma giant GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)’s artificial intelligence (AI)-driven drug discovery platform.
Breaking therapy resistance of follicular lymphoma
Latest NewsSwiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy.
Tiziana Life Sciences: Putting research first
AppointmentsAIM-listed Tiziana Life Sciences has a new head: The clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases appointed Kunwar Shailubhai Chief Executive Officer and Chief Scientific Officer.
AML: Cellectis testing allogenic CAR-T cell therapy
Latest NewsGenome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.
Diabetes: J&J and Seventure Partners launch investment
Latest NewsEuropean venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, the company’s app analyses the individual microbiome to predict blood sugar responses to thousands of different foods.
€66m Life Sciences Fund focused on Germany and Benelux
Latest NewsVenture Capitalist Biogeneration Ventures has exceeded the target size of its life sciences fund BGV III through investments from the European Investment Bank’s InnovFin Equity Facility and the Dutch Venture Initiative II.